Pegvisomant



Indications and Reactions:

Role Indications Reactions
Primary
Acromegaly 41.4%
Hypertension 20.9%
Type 2 Diabetes Mellitus 6.8%
Pain 4.0%
Blood Thyroid Stimulating Hormone Decreased 3.2%
Osteoporosis 3.2%
Ewing's Sarcoma 2.9%
Lipid Metabolism Disorder 2.5%
Supplementation Therapy 2.2%
Lipids Abnormal 1.8%
Bone Pain 1.4%
Depression 1.4%
Dyspnoea 1.4%
Prostate Cancer 1.4%
Follicle-stimulating Hormone Deficiency 1.1%
Hypocalcaemia 1.1%
Luteinising Hormone Deficiency 1.1%
Anxiety 0.7%
Gastrooesophageal Reflux Prophylaxis 0.7%
Gout 0.7%
Death 13.0%
Cholelithiasis 10.4%
Pituitary Tumour Benign 6.5%
Pneumonia 6.5%
Arthralgia 5.2%
Cholecystitis Acute 5.2%
Hypercholesterolaemia 5.2%
Pulmonary Embolism 5.2%
Adrenal Neoplasm 3.9%
Diplopia 3.9%
Haemorrhage 3.9%
Headache 3.9%
Insulin-like Growth Factor Increased 3.9%
Pituitary Tumour Recurrent 3.9%
Septic Shock 3.9%
Spinal Compression Fracture 3.9%
Vertigo 3.9%
Anaphylactic Reaction 2.6%
Atrial Fibrillation 2.6%
Cardiac Aneurysm 2.6%
Secondary
Acromegaly 49.0%
Hypertension 11.8%
Osteoporosis 6.9%
Type 2 Diabetes Mellitus 5.9%
Lipids Abnormal 4.9%
Hypocalcaemia 2.9%
Anxiety 2.0%
Blood Thyroid Stimulating Hormone Decreased 2.0%
Insulin-like Growth Factor Increased 2.0%
Lipid Metabolism Disorder 2.0%
Tongue Neoplasm Malignant Stage Unspecified 2.0%
Cardiovascular Disorder 1.0%
Depression 1.0%
Gastrooesophageal Reflux Disease 1.0%
Nausea 1.0%
Neuralgia 1.0%
Pain 1.0%
Pituitary Tumour 1.0%
Primary Hypothyroidism 1.0%
Vomiting 1.0%
Oedema 14.6%
Arthralgia 9.8%
Hypercholesterolaemia 9.8%
Pituitary Tumour 9.8%
Spinal Compression Fracture 7.3%
Asthenia 4.9%
Neoplasm Progression 4.9%
Neoplasm Recurrence 4.9%
Urinary Tract Infection 4.9%
Urticaria 4.9%
Anal Fissure 2.4%
Drug Ineffective 2.4%
Hyponatraemia 2.4%
Lipodystrophy Acquired 2.4%
Pituitary Tumour Benign 2.4%
Pituitary Tumour Recurrent 2.4%
Pituitary Tumour Removal 2.4%
Pneumonitis 2.4%
Prostate Cancer 2.4%
Streptococcus Test Positive 2.4%
Concomitant
Acromegaly 91.7%
Carcinoid Syndrome 8.3%
Vomiting 30.8%
Pituitary Tumour Removal 15.4%
Weight Decreased 15.4%
Constipation 7.7%
Neoplasm 7.7%
Rash 7.7%
Stress Urinary Incontinence 7.7%
Transient Ischaemic Attack 7.7%